2016 ACR/ARHP Annual Meeting

November 11-16, 2016. Washington, DC.

View by Number View by Title View Sessions

View by Date

Sunday, November 13, 2016

9:00AM-11:00AM: Abstract Number: 849

Collagen Formation/Degradation Neoepitopes Are Promising Biomarkers for Systemic Sclerosis

Systemic Sclerosis, Fibrosing Syndromes, and Raynaud's – Clinical Aspects and Therapeutics - Poster I

9:00AM-11:00AM: Abstract Number: 804

Combined-Phenotype Meta-GWAS in Systemic Sclerosis and Rheumatoid Arthritis Identifies IRF4 As a New Common Susceptibility Locus

Systemic Sclerosis, Fibrosing Syndromes and Raynaud's – Pathogenesis, Animal Models and Genetics - Poster I

9:00AM-11:00AM: Abstract Number: 450

Coming Full Circle with the Omeract RA Flare Questionnaire (RA-FQ): Further Evaluation of the Properties, Meaningfulness, and Utility through Rasch Analysis and Feedback from RA Patients

Quality Measures and Quality of Care - ARHP Poster

9:00AM-11:00AM: Abstract Number: 187

Commensal Microbiota Tune Systemic Toll-like Receptor-Mediated Inflammatory Responses

Innate Immunity and Rheumatic Disease - Poster I

9:00AM-11:00AM: Abstract Number: 43

Comorbid Development of Fibromyalgia and Posttraumatic Stress Disorder after Exposure to a Combat Environment

Fibromyalgia, Soft Tissue Disorders, Regional and Specific Clinical Pain Syndromes - Poster I: Basic Science Focus

9:00AM-11:00AM: Abstract Number: 397

Comorbidities Associated with Pediatric Psoriatic Arthritis

Pediatric Rheumatology – Clinical and Therapeutic Aspects - Poster I: Juvenile Idiopathic Arthritis, Uveitis

9:00AM-11:00AM: Abstract Number: 407

Comparability of Proxy, Adolescent and Adult Measures of Functional Ability in Adolescents with JIA

Pediatric Rheumatology – Clinical and Therapeutic Aspects - Poster I: Juvenile Idiopathic Arthritis, Uveitis

9:00AM-11:00AM: Abstract Number: 149

Comparation of Ultrasonic Imaging of Enthesopathy in the Lower Extremity in Patients with Psoriatic Arthritis, Psoriasis and Other Inflammatory Arthritis

Imaging of Rheumatic Diseases - Poster I: Ultrasound and Emerging Technologies

9:00AM-11:00AM: Abstract Number: 311

Comparative Effectiveness of Ayurveda and Conventional Care in Knee Osteoarthritis – a Randomized Controlled Trial

Osteoarthritis – Clinical Aspects - Poster I

9:00AM-11:00AM: Abstract Number: 597

Comparative Effectiveness of Different Anti-TNF Drugs As First Biological DMARD in RA: Results from the Nationwide Swedish Register 2010-2015

Rheumatoid Arthritis – Small Molecules, Biologics and Gene Therapy - Poster I

9:00AM-11:00AM: Abstract Number: 632

Comparative Improvement in Health-Related Quality of Life for RA Patients Between TNF-α Inhibitors, Other Biologics, and Tofacitinib: Results from a US-Wide Observational Study

Rheumatoid Arthritis – Small Molecules, Biologics and Gene Therapy - Poster I

9:00AM-11:00AM: Abstract Number: 226

Comparing the Burden of Illness of Patients with Tophaceous and Non-Tophaceous Gout in France, Germany, Italy, Spain, UK, and USA

Metabolic and Crystal Arthropathies - Poster I: Clinical Practice

9:00AM-11:00AM: Abstract Number: 442

Comparison of Adherence and Dosing Interval of Subcutaneous Anti-TNF Biologics in Inflammatory Arthritis from a Canadian Administrative Database.

Quality Measures and Quality of Care - Poster I

9:00AM-11:00AM: Abstract Number: 507

Comparison of Body Mass Index, Anti-Citrullinated Peptides Antibodies Status and Periodontal Condition in First Degree Relatives Individuals to Rheumatoid Arthritis

Rheumatoid Arthritis – Clinical Aspects - Poster I: Clinical Characteristics/Presentation/Prognosis

9:00AM-11:00AM: Abstract Number: 32

Comparison of Effects of Leukocyte-RICH and Leukocyte-Poor Platelet-RICH Plasma on PAIN and Functionality in Patients with Lateral Epicondylitis

Fibromyalgia, Soft Tissue Disorders, Regional and Specific Clinical Pain Syndromes - Poster I: Basic Science Focus

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].